Bausch Health (BHC) Deal for Synergy Assets 'Makes Strategic Sense' - Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St indexes eye weekly losses; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.
December 12, 2018 6:30 AM ESTStrategic Acquisition Will Enhance the Salix Gastroenterology Portfolio
LAVAL, Quebec, Dec. 12, 2018 /PRNewswire/ --Â Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has entered into a definitive agreement to acquire certain assets of Synergy Pharmaceuticals Inc. (NASD: SGYP) ("Synergy") in a transaction valued at approximately $200 million plus certain assumed liabilities. Synergy filed a voluntary petition for reorganization under Chapter 11 of the U.S. Code (the "Bankruptcy Code") with the U.S. Bankruptcy Court for the... More
